By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Multi User License - $2,999
Coming Soon
A minimally invasive procedure called a cardiac catheterization uses a catheter to get access to the heart’s blood-filled chambers and coronary circulation. It is done for both interventional and diagnostic purposes.
One of the many diagnostic procedures and tests used in cardiology is coronary catheterization.
Angiocardiography specifically enables the identification of occlusion, stenosis, restenosis, thrombosis, or aneurysmal enlargement of the coronary artery lumens, heart chamber size, heart muscle contraction performance, and some aspects of heart valve function through the injection of a liquid radiocontrast agent and illumination with X-rays.
For up to 2-3% of patients, cardiac catheterization frequently required multiple hours and resulted in serious consequences.
Simple coronary catheterization tests are now routinely performed more quickly and with noticeably better results because of numerous incremental advancements throughout time.
The Global Coronary Catheters market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.
The iCross Coronary Imaging Catheter, a product or tool created to enhance the deliverability of the company’s market-leading intravascular ultrasound technology, the iLab Ultrasound Imaging System, was introduced today by Boston Scientific Corporation.
Doctors may view precise images of the heart and coronary arteries inside the body thanks to IVUS technology. The iCross Catheter will be readily available in the United States, according to the company.
The iCross Coronary Imaging Catheter from Boston Scientific is an effective tool for identifying coronary intravascular pathology, particularly in individuals with complicated coronary artery disease.
They anticipate that the enhancements iCross provides to doctors and their patients will further bolster our dominance in intravascular ultrasonography. A wide variety of interventional medical specialties employ products developed, produced, and marketed by Boston Scientific on a global scale.
The XO Cross Support Catheter Platform from Transit Scientific has received FDA approval for coronary usage. The platform is intended to facilitate wire exchanges, provide a conduit for the supply of saline solutions or diagnostic contrast agents, and guide and support a guidewire during access of the peripheral or coronary arteries.
The XO Cross Support Catheter platform is made to offer new degrees of pushability, trackability, flexibility, and torque responsiveness for access in tortuosity and difficult lesions. High fatigue resistance against challenging complicated lesions present in advanced coronary artery disease (CAD), peripheral artery disease (PAD), and critical limb ischemia is provided by the non-tapered metal-alloy and polymer construction (CLI).
The Prevail drug coated balloon (DCB) Catheter has been introduced in Europe under the CE (Conformité Européenne) label, according to an announcement from Medtronic plc, the world leader in medical technology.
The Prevail DCB, which is the most recent coronary DCB on the market, is used during percutaneous coronary intervention (PCI) operations to treat blocked or restricted coronary arteries in people with coronary artery disease (CAD). The Prevail DCB treats de novo lesions, small vascular disease, and in-stent restenosis using paclitaxel, a medication with fast absorption (ISR).
